Mark Allan Kay MD
Clinical Biochemical Genetics, Clinical Genetics, Medical Biochemical Genetics
Professor, Pediatrics -Human Gene Therapy, and Dept of Genetics Stanford University Medical Center
Join to View Full Profile
269 Campus Dr rm 2105Stanford universityStanford, CA 94305
Phone+1 650-498-6531
Dr. Kay is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Baylor College of MedicinePost-Doctoral Fellowship, Clinical Biochemical Genetics, 1990 - 1993- Baylor College of Medicine (Houston)Residency, Pediatrics, 1987 - 1990
OtherClass of 1987
Certifications & Licensure
CA State Medical License 2000 - 2020
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1997
- Whos Who in Medicine and Healthcare Marquis Whos Who
Publications & Presentations
PubMed
- 2 citationsSelective Microvascular Tissue Transfection Using Minicircle DNA for Systemic Delivery of Human Coagulation Factor IX in a Rat Model Using a Therapeutic Flap.Peter A. Than, Christopher R. Davis, Robert C. Rennert, Shane D. Morrison, Michael Findlay
Plastic and Reconstructive Surgery. 2021-11-10 - 12 citationsThe 3'tsRNAs are aminoacylated: Implications for their biogenesis.Ziwei Liu, Hak Kyun Kim, Jianpeng Xu, Yuqing Jing, Mark A. Kay
Plos Genetics. 2021-07-29 - 45 citationsRNA structure probing reveals the structural basis of Dicer binding and cleavage.Qing-Jun Luo, Jinsong Zhang, Pan Li, Qing Wang, Yue Zhang
Nature Communications. 2021-06-07
Lectures
- Biologic Therapeutics Seminar Series - Systems Approaches to Antibody-based Immunotherapy of CancerWashington University School of Medicine, Saint Louis, Missouri - 5/16/2012
- Biologic Therapeutics Seminar Series - Hairy Cell Leukemia, Standard & Biologic ApproachesWashington University School of Medicine, Saint Louis, Missouri - 2/22/2012
- Biologic Therapeutics Seminar Series - In Vivo Gene Transfer for Genetic Disease: Progress & ChallengesWashington University School of Medicine, Saint Louis, Missouri - 1/25/2012
Press Mentions
LogicBio Acquired by Alexion, AstraZeneca Rare DiseaseOctober 3rd, 2022- Mystery Hepatitis Cases in Kids Linked to Unexpected Viral SuspectJuly 25th, 2022
- Nuevocor Closes US$24M Series A Financing to Advance Novel Gene Therapies for CardiomyopathiesJune 18th, 2021
- Join now to see all
Grant Support
- 3' tsRNAs: biologic function and pre-clinical targeting for treating human diseaseSTANFORD UNIVERSITY2023–2028
- 3' tsRNAs: biologic function and pre-clinical targeting for treating human diseaseSTANFORD UNIVERSITY2023–2028
- 3' tsRNAs: biologic function and pre-clinical targeting for treating human diseaseSTANFORD UNIVERSITY2023–2028
- 3' tsRNAs: biologic function and pre-clinical targeting for treating human diseaseSTANFORD UNIVERSITY2023–2028
- 3' tsRNAs: biologic function and pre-clinical targeting for treating human diseaseSTANFORD UNIVERSITY2023–2028
- Hepatic gene transfer for the treatment of hemophilia B and other genetic diseasesSTANFORD UNIVERSITY2000–2027
- Hepatic gene transfer for the treatment of hemophilia B and other genetic diseasesSTANFORD UNIVERSITY2000–2027
- Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseasesSTANFORD UNIVERSITY2006–2026
- Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseasesSTANFORD UNIVERSITY2006–2026
- Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseasesSTANFORD UNIVERSITY2006–2026
- Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseasesSTANFORD UNIVERSITY2006–2026
- Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseasesSTANFORD UNIVERSITY2006–2026
- Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseasesSTANFORD UNIVERSITY2006–2026
- Gene Therapy for DiabetesOREGON HEALTH & SCIENCE UNIVERSITY2019–2025
- AAV capsid engineering for enhancing gene transferSTANFORD UNIVERSITY2015–2025
- Molecular Evolution Strategies To Derive New Recombinant AAV VectorsNational Heart, Lung, And Blood Institute2009–2012
- Novel Sources Of Transplantable Beta-Cell ReplacementsNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2011
- Studies On RNAI Based Delivery In VivoNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2011
- RNAI For The Treatment Of Viral HepatitisNational Institute Of Allergy And Infectious Diseases2006–2011
- Improved Adenoviral Vectors For Hepatic Gene TherapyNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2006
- RNAI - Based Therapies For HCV InfectionNational Institute Of Allergy And Infectious Diseases2005
- Novel Aavs For Gene TherapyNational Heart, Lung, And Blood Institute2005
- Gene Therapy For HemophiliaNational Heart, Lung, And Blood Institute2005
- Gene Therapy For Hemophilia And Coronary Artery DiseaseNational Heart, Lung, And Blood Institute2000–2004
- Transposon Based Gene TherapeuticsNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2002
- Core--Vector ProductionNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2002
- Mouse Model For HCV InfectionNational Institute Of Allergy And Infectious Diseases2000–2002
- Isolated Liver Perfusion Raav &Nonviral Vector DeliveryNational Heart, Lung, And Blood Institute2000–2002
- Conference On Gene Therapy 2001: A Gene OdysseyNational Institute Of Diabetes And Digestive And Kidney Diseases2001
- Adjunct Immunotherapy For Adenoviral Gene TherapyNational Institute Of Diabetes And Digestive And Kidney Diseases1998–1999
- Hepatic Gene Transfer For The Treatment Of Hemophilia BNational Heart, Lung, And Blood Institute1998–1999
- Preclinical Hepatic Gene TherapyNational Center For Research Resources1997–1999
- Pilot Study--Hepatic Gene Therapy For Hemophilia ANational Institute Of Diabetes And Digestive And Kidney Diseases1996–1999
- Core--Vector FacilityNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1999
- Gene TherapyNational Institute Of Allergy And Infectious Diseases1996–1999
- Animal ModelsNational Institute Of Allergy And Infectious Diseases1996–1999
- Adjunct Immunotherapy For Adenoviral Gene TherapyNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1997
- Hepatic Gene Transfer For The Treatment Of Hemophilia BNational Heart, Lung, And Blood Institute1995–1997
- Improved Adenoviral Vectors For Hepatic Gene TherapyNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1997
- Hepatic Gene TherapyNational Institute Of General Medical Sciences1990–1992
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
